Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.

doi:10.1200/PO.23.00338

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.

JCO precision oncology - 1 Sept 2023

Yndestad Synnøve, Engebrethsen Christina, Herencia-Ropero Andrea, Nikolaienko Oleksii, Vintermyr Olav K, Lillestøl Reidun K, Minsaas Laura, Leirvaag Beryl, Iversen Gjertrud T, Gilje Bjørnar, Blix Egil S, Espelid Helge, Lundgren Steinar, Geisler Jürgen, Aase Hildegunn S, Aas Turid, Gudlaugsson Einar G, Llop-Guevara Alba, Serra Violeta, Janssen Emiel A M, Lønning Per E, Knappskog Stian, Eikesdal Hans P

Abstract excerpt

PURPOSE: Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer. METHODS: HRD status was established using targeted gene panel sequencing (360 genes) and BRCA1 methylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Mechanisms

Share to Genes, BRCA2

Share to Genetic factors in colorectal cancer

Share to Homologous Recombination

Share to Mutation

Share to PARP inhibition in cancer therapy

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38039432
DOI: 10.1200/PO.23.00338
PMCID: PMC10703128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.PMID 38039432Read ↗

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.Semantic proximity Read ↗

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read ↗

Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancerSemantic proximity Read ↗

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.Semantic proximity Read ↗

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Semantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureSemantic proximity Read ↗

Pan-cancer landscape of homologous recombination deficiency.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.